UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid litigation over alleged cancer risks. The Florida State Court ruled in ...
Twelve days after GSK secured a key win in Florida, with a state court tossing expert testimony on the cancer-causing ...
GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn ...
GSK (NYSE:GSK) stock was up 3% in afternoon trading Tuesday in the wake of a ruling by a Delaware court on whether certain ...
(Reuters) – GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman’s illness, a ...